#United States #San Diego #Class Action #Robbins LLP #ADMA Biologics

Robbins LLP Issues Warning for ADMA Investors

In a significant development for shareholders of ADMA Biologics, Inc., Robbins LLP is highlighting a critical deadline for investors caught up in a recent class action lawsuit. Shareholders of the biopharmaceutical company have until August 10, 2026, to file their papers in this case, which addresses allegations of misleading business practices.

ADMA Biologics, listed on NASDAQ under the ticker ADMA, focuses on the development and marketing of plasma-derived biologics aimed at treating immune deficiencies and infectious diseases. The lawsuit encompasses investors who purchased or acquired shares between August 9, 2024, and March 25, 2026. This class period marks a time when the company allegedly engaged in dubious practices that misled investors regarding its operational status.

Allegations Against ADMA Biologics

Investors have raised serious allegations regarding ADMA's operations during this period. According to the filed complaint, the company is accused of making false statements and failing to disclose essential information, severely affecting the trust and financial standing of its shareholders.

Some key allegations include:

• - Undisclosed Related Party Transactions: It is alleged that ADMA engaged in transactions with related parties that were not disclosed to investors, raising concerns about transparency and governance within the company.
• - Channel Stuffing: The complaint indicates that ADMA employed a practice known as channel stuffing, which artificially inflates revenue figures, creating a misleading appearance of growth.
• - Lack of Internal Controls: The lawsuit claims that ADMA did not have adequate internal controls, jeopardizing the integrity of its financial reporting.

The controversy escalated following a report published by Culper Research on March 24, 2026. This report significantly impacted ADMA’s market performance by indicating that the supposed growth reported by the company was significantly overstated, primarily driven by channel stuffing. Following this revelation, ADMA's stock plummeted, dropping $2.26 (16.6%) to close at $11.33 per share, and further fell $1.70 (15.0%) the next day, reflecting the immediate market reaction to the allegations.

Eligibility for the Class Action

ADMA shareholders who believe they are eligible to act as lead plaintiffs must file their documents with the court by the August deadline. The lead plaintiff plays a crucial role by representing the interests of other shareholders in the ongoing litigation. It's important to note that participation in the lawsuit is not a prerequisite for being eligible for recovery. Investors who do not wish to actively participate can remain members of the class without losing their right to recover potential losses.

Robbins LLP operates on a contingency fee basis, which means that shareholders incur no fees or expenses unless the case results in a successful recovery.

About Robbins LLP

As a prominent firm specializing in shareholder rights litigation, Robbins LLP has a robust track record of securing substantial recoveries for investors, having restored over $1 billion in value to shareholders and achieved significant governance reforms across numerous Fortune 1000 companies. Brian J. Robbins, the firm's founding partner, emphasizes a commitment to accountability and corporate transparency as central tenets of their practice.

For shareholders interested in receiving updates on the progress of the ADMA Biologics class action lawsuit or any corporate misconduct updates, Robbins LLP encourages signing up for their Stock Watch alerts. This service keeps investors informed and enables them to act quickly regarding their rights and recoveries.

As the August 10 deadline approaches, affected shareholders are urged to take immediate action to protect their interests and seek justice in light of these troubling allegations against ADMA Biologics.